Tags

Type your tag names separated by a space and hit enter

The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
Eur J Cancer. 2012 Sep; 48(14):2260-9.EJ

Abstract

Cytochalasin D targets actin and is ubiquitous in eukaryotic cells. When cytochalasin D is used as a cytotoxic agent in cancer therapy, it causes significant side effects. To prevent this, cytochalasin D can be encapsulated in polyethylene liposomes. In this study, high-performance liquid chromatography observation of the biodistribution of pegylated liposomal cytochalasin D in tumour-bearing mice showed that liposomal cytochalasin D could be conveniently dissolved in water for i.v. injection and that it specifically accumulated in tumour tissues, more than natural cytochalasin D did. The half-time of liposomal cytochalasin D in the plasma was also significantly longer than that of natural cytochalasin D (4h versus 10 min). MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that liposomal cytochalasin D treatment could cause significant inhibition of cell proliferation in vitro in a manner similar to that of natural cytochalasin D. The antitumour activities of liposomal cytochalasin D were investigated in B16 melanoma, CT26 colorectal carcinoma and H22 hepatoma models, and the results indicated that liposomal cytochalasin D could significantly inhibit tumour growth and prolong survival in a manner similar to that of cisplatin. TUNEL-based apoptosis assays showed that liposomal cytochalasin D induced significant tumour cell apoptosis. Significant inhibition of tumour angiogenesis was observed in mice treated with liposomal cytochalasin D. In addition, no significant side effects were observed in mice treated with liposomal cytochalasin D. Our results show that liposomal cytochalasin D increases solubility and bioavailability, a lower incidence of side effects and improves antitumour effects, indicating its potential as a chemical agent for cancer therapy.

Authors+Show Affiliations

Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Haikou, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22257793

Citation

Huang, Feng-ying, et al. "The Antitumour Activities Induced By Pegylated Liposomal Cytochalasin D in Murine Models." European Journal of Cancer (Oxford, England : 1990), vol. 48, no. 14, 2012, pp. 2260-9.
Huang FY, Mei WL, Li YN, et al. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models. Eur J Cancer. 2012;48(14):2260-9.
Huang, F. Y., Mei, W. L., Li, Y. N., Tan, G. H., Dai, H. F., Guo, J. L., Wang, H., Huang, Y. H., Zhao, H. G., Zhou, S. L., Li, L., & Lin, Y. Y. (2012). The antitumour activities induced by pegylated liposomal cytochalasin D in murine models. European Journal of Cancer (Oxford, England : 1990), 48(14), 2260-9. https://doi.org/10.1016/j.ejca.2011.12.018
Huang FY, et al. The Antitumour Activities Induced By Pegylated Liposomal Cytochalasin D in Murine Models. Eur J Cancer. 2012;48(14):2260-9. PubMed PMID: 22257793.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The antitumour activities induced by pegylated liposomal cytochalasin D in murine models. AU - Huang,Feng-ying, AU - Mei,Wen-li, AU - Li,Yue-nan, AU - Tan,Guang-hong, AU - Dai,Hao-fu, AU - Guo,Jun-li, AU - Wang,Hua, AU - Huang,Yong-hao, AU - Zhao,Huan-ge, AU - Zhou,Song-lin, AU - Li,Ling, AU - Lin,Ying-ying, Y1 - 2012/01/16/ PY - 2011/10/22/received PY - 2011/12/17/accepted PY - 2012/1/20/entrez PY - 2012/1/20/pubmed PY - 2012/11/3/medline SP - 2260 EP - 9 JF - European journal of cancer (Oxford, England : 1990) JO - Eur J Cancer VL - 48 IS - 14 N2 - Cytochalasin D targets actin and is ubiquitous in eukaryotic cells. When cytochalasin D is used as a cytotoxic agent in cancer therapy, it causes significant side effects. To prevent this, cytochalasin D can be encapsulated in polyethylene liposomes. In this study, high-performance liquid chromatography observation of the biodistribution of pegylated liposomal cytochalasin D in tumour-bearing mice showed that liposomal cytochalasin D could be conveniently dissolved in water for i.v. injection and that it specifically accumulated in tumour tissues, more than natural cytochalasin D did. The half-time of liposomal cytochalasin D in the plasma was also significantly longer than that of natural cytochalasin D (4h versus 10 min). MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that liposomal cytochalasin D treatment could cause significant inhibition of cell proliferation in vitro in a manner similar to that of natural cytochalasin D. The antitumour activities of liposomal cytochalasin D were investigated in B16 melanoma, CT26 colorectal carcinoma and H22 hepatoma models, and the results indicated that liposomal cytochalasin D could significantly inhibit tumour growth and prolong survival in a manner similar to that of cisplatin. TUNEL-based apoptosis assays showed that liposomal cytochalasin D induced significant tumour cell apoptosis. Significant inhibition of tumour angiogenesis was observed in mice treated with liposomal cytochalasin D. In addition, no significant side effects were observed in mice treated with liposomal cytochalasin D. Our results show that liposomal cytochalasin D increases solubility and bioavailability, a lower incidence of side effects and improves antitumour effects, indicating its potential as a chemical agent for cancer therapy. SN - 1879-0852 UR - https://www.unboundmedicine.com/medline/citation/22257793/The_antitumour_activities_induced_by_pegylated_liposomal_cytochalasin_D_in_murine_models_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(11)01067-7 DB - PRIME DP - Unbound Medicine ER -